Bristol Myers Squibb Co. raised its 2024 earnings guidance after reporting better-than-expected revenue and profit, fueled by demand for the blood-thinner Eliquis and several newer treatments.Adjusted ...
Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...
9d
ANSWER: In general, I recommend against stopping prescription medications without your doctor telling you to, and I hope to ...
Bristol Myers Squibb’s third-quarter results benefited from sales of its legacy brands Eliquis and Revlimid, as well as ...
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
The company reported $11.9B in revenue for the quarter with ~8% YoY growth as its blockbuster drugs Revlimid and Eliquis surpassed expectations, while sales from cancer therapy Opdivo slightly ...
Bristol Myers Squibb posted better-than-expected third-quarter earnings on Thursday citing strong sales of established drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback